Evidence map›Paper›PMID 26354054›Full record

Trial reportThe Korean journal of internal medicine2015

Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study.

Tae Yoon Lee, Jung Sik Choi, Hyoung-Chul Oh, Tae Jun Song, Jae Hyuk Do, Young Koog Cheon

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Korean journal of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Tae Yoon LeeDivision of Gastroenterology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
Jung Sik ChoiDivision of Gastroenterology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
Hyoung-Chul OhDivision of Gastroenterology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Tae Jun SongDivision of Gastroenterology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
Jae Hyuk DoDivision of Gastroenterology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Young Koog CheonDivision of Gastroenterology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
Chung-Ang University · KRKonkuk University · KRInje University Busan Paik Hospital · KRInje University Ilsan Paik Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsAcute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Combination therapy w ith ora l udenafil and aceclofenac may reduce the occurrence of post-ERCP pancreatitis by targeting different pathophysiological mechanisms. We investigated whether combining udenafil and aceclofenac reduced the rates of post-ERCP pancreatitis.

methodsA prospective, randomized, double-blind, placebo-controlled, multicenter study was conducted in four academic medical centers. Between January 2012 and June 2013, a total of 216 patients who underwent ERCP were analyzed for the occurrence of post-ERCP pancreatitis. Patients were determined to be at high risk for pancreatitis based on validated patient and procedure-related risk factors.

resultsDemographic features, indications for ERCP, and therapeutic procedures were similar in each group. There were no significant differences in the rate (15.8% [17/107] vs. 16.5% [18/109], p = 0.901) and severity of post-ERCP pancreatitis between the udenafil/aceclofenac and placebo groups. One patient in each group developed severe pancreatitis. Multivariate analyses indicated that suspected dysfunction of the sphincter of Oddi and endoscopic papillary balloon dilation without sphincterotomy were associated with post-ERCP pancreatitis.

conclusionsCombination therapy with udenafil and aceclofenac is not effective for the prevention of post-ERCP pancreatitis.

Indexed as

Acute DiseaseAdministration, OralAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalBenzenesulfonamidesCholangiopancreatography, Endoscopic RetrogradeDiclofenacDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultivariate AnalysisaceclofenacAnti-Inflammatory Agents, Non-SteroidalBenzenesulfonamidesDiclofenacPhosphodiesterase 5 InhibitorsPyrimidinesSulfonamidesudenafilAceclofenacCholangiopancreatography, endoscopic retrogradePancreatitisUdenafil

Identifiers

PMID26354054
PMCPMC4578023
OpenAlexW2121402788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.